×
About 13,593 results

ALLMedicine Idiopathic Pulmonary Fibrosis Center

Research & Reviews  6,381 results

Circulating Plasma Biomarkers of Survival in Anti-fibrotic Treated Patients with Idiopa...
https://doi.org/10.1016/j.chest.2020.04.066
Chest Adegunsoye A, Alqalyoobi S et. al.

May 25th, 2020 - A number of circulating plasma biomarkers have been shown to predict survival in patients with idiopathic pulmonary fibrosis (IPF), but most were identified prior to the use of anti-fibrotic therapy (AF) in this population. Because pirfenidone and...

Early left atrial dysfunction in idiopathic pulmonary fibrosis patients without chronic...
https://doi.org/10.1007/s10554-020-01887-5
The International Journal of Cardiovascular Imaging; Sonaglioni A, Caminati A et. al.

May 24th, 2020 - No data are actually available regarding the left atrial (LA) functional assessment by two-dimensional speckle tracking echocardiography (2D-STE) in early-stage idiopathic pulmonary fibrosis (IPF). The primary end-point of our study was to assess ...

Subclinical liver fibrosis in patients with idiopathic pulmonary fibrosis.
https://doi.org/10.1007/s11739-020-02376-2
Internal and Emergency Medicine; Cocconcelli E, Tonelli R et. al.

May 24th, 2020 - Data on the presence of subclinical fibrosis across multiple organs in patients with idiopathic lung fibrosis (IPF) are lacking. Our study aimed at investigating through hepatic transient elastography (HTE) the prevalence and clinical impact of su...

Pamrevlumab for the treatment of idiopathic pulmonary fibrosis.
https://doi.org/10.1080/13543784.2020.1773790
Expert Opinion on Investigational Drugs; Sgalla G, Franciosa C et. al.

May 22nd, 2020 - The two available therapies for idiopathic pulmonary fibrosis (IPF), pirfenidone and nintedanib, slow down but do not halt IPF progression. Hence, in the last few years, several agents with specific molecular targets have been investigated to find...

Single versus bilateral lung transplantation in idiopathic pulmonary fibrosis: A system...
https://doi.org/10.1371/journal.pone.0233732
PloS One; Li D, Liu Y et. al.

May 21st, 2020 - Lung transplantation remains the only curative treatment for end-stage lung disease, conferring a better survival for some IPF patients, but whether they should receive double lung transplantation (DLT) or single lung transplantation (SLT) is stil...

see more →

Guidelines  15 results

Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice G...
https://www.atsjournals.org/doi/10.1164/rccm.201807-1255ST
Raghu, G.

Aug 31st, 2018 - This document provides clinical recommendations for the diagnosis of idiopathic pulmonary fibrosis (IPF). It represents a collaborative effort between the American Thoracic Society, European Respiratory Society, Japanese Respiratory Society, and.

Use of Animal Models for the Preclinical Assessment of Potential Therapies for Pulmonary Fib...
http://www.thoracic.org/statements/resources/interstitial-lung-disease/animal-models-pulm-fibrosis.pdf
R. Gisli Jenkins

Apr 30th, 2017 - Numerous compounds have shown efficacy in limiting development of pulmonary fibrosis using animal models, yet few of these compounds have replicated these beneficial effects in clinical trials. Given the challenges associated with performing clini.

Idiopathic Pulmonary Fibrosis in Switzerland: Diagnosis and Treatment.
https://doi.org/10.1159/000464332
Respiration; International Review of Thoracic Diseases; Funke-Chambour M, Azzola A et. al.

Mar 27th, 2017 - Idiopathic pulmonary fibrosis (IPF) is a severe progressive and irreversible lung disease. Novel antifibrotic drugs that slow disease progression are now available. However, many issues regarding patient management remain unanswered, such as the c...

The Intersection of GERD, Aspiration, and Lung Transplantation.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4948126
Journal of Laparoendoscopic & Advanced Surgical Techniques. Part A; Patti MG, Vela MF et. al.

May 24th, 2016 - Lung transplantation is a radical but life-saving treatment option for patients with end-stage lung diseases, such as idiopathic pulmonary fibrosis (IPF) and scleroderma. In light of the proposed association and controversy linking gastroesophagea...

Treatment of Idiopathic Pulmonary Fibrosis.
https://doi.org/10.1513/AnnalsATS.201510-713CME
Annals of the American Thoracic Society; Carlos WG, Strek ME et. al.

Jan 5th, 2016 - Treatment of Idiopathic Pulmonary Fibrosis.|2016|Carlos WG,Strek ME,Wang TS,Patel H,Raghu G,|drug therapy,

see more →

Drugs  4 results see all →

Clinicaltrials.gov  6,745 results

Circulating Plasma Biomarkers of Survival in Anti-fibrotic Treated Patients with Idiopa...
https://doi.org/10.1016/j.chest.2020.04.066
Chest Adegunsoye A, Alqalyoobi S et. al.

May 25th, 2020 - A number of circulating plasma biomarkers have been shown to predict survival in patients with idiopathic pulmonary fibrosis (IPF), but most were identified prior to the use of anti-fibrotic therapy (AF) in this population. Because pirfenidone and...

Early left atrial dysfunction in idiopathic pulmonary fibrosis patients without chronic...
https://doi.org/10.1007/s10554-020-01887-5
The International Journal of Cardiovascular Imaging; Sonaglioni A, Caminati A et. al.

May 24th, 2020 - No data are actually available regarding the left atrial (LA) functional assessment by two-dimensional speckle tracking echocardiography (2D-STE) in early-stage idiopathic pulmonary fibrosis (IPF). The primary end-point of our study was to assess ...

Subclinical liver fibrosis in patients with idiopathic pulmonary fibrosis.
https://doi.org/10.1007/s11739-020-02376-2
Internal and Emergency Medicine; Cocconcelli E, Tonelli R et. al.

May 24th, 2020 - Data on the presence of subclinical fibrosis across multiple organs in patients with idiopathic lung fibrosis (IPF) are lacking. Our study aimed at investigating through hepatic transient elastography (HTE) the prevalence and clinical impact of su...

Pamrevlumab for the treatment of idiopathic pulmonary fibrosis.
https://doi.org/10.1080/13543784.2020.1773790
Expert Opinion on Investigational Drugs; Sgalla G, Franciosa C et. al.

May 22nd, 2020 - The two available therapies for idiopathic pulmonary fibrosis (IPF), pirfenidone and nintedanib, slow down but do not halt IPF progression. Hence, in the last few years, several agents with specific molecular targets have been investigated to find...

Single versus bilateral lung transplantation in idiopathic pulmonary fibrosis: A system...
https://doi.org/10.1371/journal.pone.0233732
PloS One; Li D, Liu Y et. al.

May 21st, 2020 - Lung transplantation remains the only curative treatment for end-stage lung disease, conferring a better survival for some IPF patients, but whether they should receive double lung transplantation (DLT) or single lung transplantation (SLT) is stil...

see more →

News  443 results

Fast Five Quiz: Idiopathic Pulmonary Fibrosis
https://www.medscape.com/viewarticle/925452

Apr 29th, 2020 - Idiopathic pulmonary fibrosis (IPF) is a devastating chronic lung disease characterized by progressive lung scarring. IPF is described on imaging as well as histopathologically by the usual interstitial pneumonia (UIP) pattern. Patients have incre...

Fast Five Quiz: Idiopathic Pulmonary Fibrosis Imaging
https://www.medscape.com/viewarticle/925458

Apr 29th, 2020 - Idiopathic pulmonary fibrosis (IPF) is a specific form of chronic, progressive fibrosing interstitial pneumonia of unknown etiology that affects approximately 3 million individuals worldwide. IPF is characterized by gradual worsening of dyspnea an...

FDA broadens nintedanib interstitial lung disease indication
https://www.mdedge.com/internalmedicine/article/218826/pulmonology/fda-broadens-nintedanib-interstitial-lung-disease?channel=39313
Mitchel L. Zoler

Mar 11th, 2020 - A new indication for the tyrosine kinase inhibitor nintedanib approved by the Food and Drug Administration on March 9, 2020, broadened the drug’s targeted population to include patients with chronic fibrosing interstitial lung diseases with a prog.

Roche Pushes to Kick-Start Lung Therapy Esbriet After Big Writedown
https://www.medscape.com/viewarticle/926124

Mar 4th, 2020 - ZURICH, March 3 (Reuters) - Roche has won U.S. breakthrough therapy status for Esbriet for unclassifiable interstitial lung disease (uILD), the company said on Tuesday, as it aims to lift disappointing revenue by expanding conditions for which it ...

Roche pushes to kick-start lung therapy Esbriet after big writedown
https://www.reuters.com/article/us-roche-esbriet/roche-pushes-to-kick-start-lung-therapy-esbriet-after-big-writedown-idUSKBN20Q21O

Mar 3rd, 2020 - FILE PHOTO: The logo of Swiss drugmaker Roche is seen at its headquarters in Basel, Switzerland January 30, 2020. REUTERS/Arnd Wiegmann/File Photo ZURICH (Reuters) - Roche has won U.S. breakthrough therapy status for Esbriet for unclassifiable int...

see more →

Patient Education  5 results see all →